Chicago Capital
VRTX icon

Chicago Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Chicago Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.16M Buy
17,519
+490
+3% +$251K 0.21% 62
2026
Q2 		$8.46M Buy
17,029
+4,910
+41% +$2.18M 0.2% 71
2026
Q1 		$5.41M Sell
12,119
-26
-0.2% -$12.1K 0.15% 81
2025
Q4 		$5.51M Sell
12,145
-679
-5% -$293K 0.14% 85
2025
Q3 		$5.02M Sell
12,824
-51
-0.4% -$21.3K 0.12% 87
2025
Q2 		$5.73M Buy
12,875
+469
+4% +$216K 0.14% 77
2025
Q1 		$6.01M Buy
12,406
+188
+2% +$87.6K 0.17% 80
2024
Q4 		$4.92M Sell
12,218
-74
-0.6% -$34.3K 0.13% 85
2024
Q3 		$5.72M Sell
12,292
-377
-3% -$181K 0.16% 78
2024
Q2 		$5.94M Buy
12,669
+282
+2% +$122K 0.18% 78
2024
Q1 		$5.18M Buy
12,387
+447
+4% +$189K 0.16% 76
2023
Q4 		$4.86M Buy
+11,940
New +$4.41M 0.17% 75

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Chicago Capital's VRTX Position: Q3 2026 in Review

Chicago Capital increased its Vertex Pharmaceuticals (VRTX) stake by 2.9% in Q3 2026, buying an estimated $251K and bringing the position to 17,519 shares worth $9.16M. The position accounts for 0.21% of the portfolio, ranked #62.

Chicago Capital first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. 1,161 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Chicago Capital held 17,519 shares of Vertex Pharmaceuticals worth $9.16M as of Q3 2026.
  • Chicago Capital bought 490 Vertex Pharmaceuticals shares in Q3 2026, an estimated $251K.
  • Vertex Pharmaceuticals made up 0.21% of Chicago Capital's portfolio in Q3 2026, its #62 holding.
  • Chicago Capital first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • 1,161 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Chicago Capital's 13F filing for Q3 2026, filed 13 Oct 2026.